Tasadenoturev
Biologicalexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00805376)
Timeline
Indications
Studied for
- Brain Neoplasms · Phase 2
- Central Nervous System Diseases · Phase 1
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Gliosarcoma · Phase 2
- Neoadjuvant Therapy · Phase 1
- Neoplasms · Phase 2
- Neoplasms, Nerve Tissue · Phase 2
- Neoplasms, Neuroepithelial · Phase 2
- Nervous System Diseases · Phase 2
- Neuroectodermal Tumors · Phase 2
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3990045 ↗
Also known as
- dnx-2401
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03178032 | Phase 1 | May 30, 2017 | Alcyone Lifesciences, Inc., Clinica Universidad de Navarra, DNAtrix, Inc. |
| NCT02798406 | Phase 2 | Jun 1, 2016 | DNAtrix, Inc., Merck |
| NCT02197169 | Phase 1 | Aug 1, 2014 | Baylor University, DNAtrix, Inc., Ohio State University, University of South Florida, University of Texas at Houston |
| NCT00805376 | Phase 1 | Feb 1, 2009 | DNAtrix, Inc., University of Texas at Houston |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DNAtrix, Inc. | For profit | 4 | 3 | 2 | 2009 |
| University of Texas at Houston | Academic/Hospital | 2 | 0 | 1 | 2009 |
| Alcyone Lifesciences, Inc. | For profit | 1 | 0 | 1 | 2017 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Clinica Universidad de Navarra | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Merck | For profit | 1 | 0 | 1 | 2016 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2014 |
8 organizations
Page 1 / 1